Skip to main content
Top
Published in: Strahlentherapie und Onkologie 5/2013

01-05-2013 | Original article

Comparison of four target volume definitions for pancreatic cancer

Guidelines for treatment of the lymphatics and the primary tumor

Authors: E. Fokas, C. Eccles, N. Patel, K.-Y. Chu, S. Warren, W. Gillies McKenna, T.B. Brunner

Published in: Strahlentherapie und Onkologie | Issue 5/2013

Login to get access

Abstract

Background and purpose

Target volume definitions for radiotherapy in pancreatic ductal adenocarcinoma (PDAC) vary substantially. Some groups aim to treat the primary tumor only, whereas others include elective lymph nodes (eLNs). eLNs close to the primary tumor are often included unintentionally within the treatment volume, depending on the respective treatment philosophies. We aimed to measure the percentages of anatomical coverage of eLNs by comparing four different contouring guidelines.

Patients and methods

Planning target volumes (PTVs) were contoured using planning computed tomography (CT) scans of 11 patients with PDAC based on the Oxford, RTOG (Radiation Therapy Oncology Group), Michigan, and SCALOP (Selective Chemoradiation in Advanced Localised Pancreatic Cancer trial) guidelines. Clinical target volumes (CTVs) included the peripancreatic, para-aortic, paracaval, celiac trunk, superior mesenteric, and portal vein lymph node areas. Volumetric comparisons of the coverage of all eLN regions were conducted to illustrate the differences between the four contouring strategies.

Results

The PTV sizes of the RTOG and Oxford guidelines were comparable. The SCALOP and Michigan PTV sizes were similar to each other and significantly smaller than the RTOG and Oxford PTVs. A large variability of eLN coverage was found for the various subregions according to the respective contouring strategies.

Conclusion

This is the first study to directly compare the percentage of anatomical coverage of eLNs according to four PTVs in the same patient cohort. Potential practical consequences are discussed in detail.
Literature
1.
go back to reference Stathis A, Moore MJ (2012) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163–172CrossRef Stathis A, Moore MJ (2012) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163–172CrossRef
2.
go back to reference Kessel KA, Habermehl D, Bohn C et al (2012) Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer. Strahlenther Onkol 188:1119–1124PubMedCrossRef Kessel KA, Habermehl D, Bohn C et al (2012) Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer. Strahlenther Onkol 188:1119–1124PubMedCrossRef
3.
go back to reference Tinkl D, Grabenbauer GG, Golcher H et al (2009) Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 185:557–566PubMedCrossRef Tinkl D, Grabenbauer GG, Golcher H et al (2009) Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 185:557–566PubMedCrossRef
4.
5.
go back to reference Iacobuzio-Donahue CA, Fu B, Yachida S et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806–1813PubMedCrossRef Iacobuzio-Donahue CA, Fu B, Yachida S et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806–1813PubMedCrossRef
6.
go back to reference Asiyanbola B, Gleisner A, Herman JM et al (2009) Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 13:752–759PubMedCrossRef Asiyanbola B, Gleisner A, Herman JM et al (2009) Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 13:752–759PubMedCrossRef
7.
go back to reference Loehrer PJ Sr, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112PubMedCrossRef Loehrer PJ Sr, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112PubMedCrossRef
8.
go back to reference Maluta S, Schaffer M, Pioli F et al (2011) Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: an open-label comparative cohort trial. Strahlenther Onkol 187:619–625PubMedCrossRef Maluta S, Schaffer M, Pioli F et al (2011) Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: an open-label comparative cohort trial. Strahlenther Onkol 187:619–625PubMedCrossRef
9.
go back to reference Eppinga W, Lagerwaard F, Verbakel W et al (2010) Volumetric modulated arc therapy for advanced pancreatic cancer. Strahlenther Onkol 186:382–387PubMedCrossRef Eppinga W, Lagerwaard F, Verbakel W et al (2010) Volumetric modulated arc therapy for advanced pancreatic cancer. Strahlenther Onkol 186:382–387PubMedCrossRef
10.
go back to reference Murphy JD, Adusumilli S, Griffith KA et al (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801–808PubMedCrossRef Murphy JD, Adusumilli S, Griffith KA et al (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801–808PubMedCrossRef
11.
go back to reference Ben-Josef E, Schipper M, Francis IR et al (2011) Phase I/II radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 81:127–128CrossRef Ben-Josef E, Schipper M, Francis IR et al (2011) Phase I/II radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 81:127–128CrossRef
12.
go back to reference Brunner TB, Scott-Brown M (2010) The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 5:64PubMedCrossRef Brunner TB, Scott-Brown M (2010) The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 5:64PubMedCrossRef
13.
go back to reference Ben-Josef E, Lawrence TS (2012) Radiotherapy: the importance of local control in pancreatic cancer. Nat Rev Clin Oncol 9:9–10CrossRef Ben-Josef E, Lawrence TS (2012) Radiotherapy: the importance of local control in pancreatic cancer. Nat Rev Clin Oncol 9:9–10CrossRef
14.
go back to reference Brunner TB, Grabenbauer GG, Klein P et al (2003) Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 55:144–153PubMedCrossRef Brunner TB, Grabenbauer GG, Klein P et al (2003) Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 55:144–153PubMedCrossRef
15.
go back to reference Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267PubMedCrossRef Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267PubMedCrossRef
16.
go back to reference Brunner TB, Merkel S, Grabenbauer GG et al (2005) Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 62:1021–1029PubMedCrossRef Brunner TB, Merkel S, Grabenbauer GG et al (2005) Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 62:1021–1029PubMedCrossRef
17.
go back to reference Brunner TB, Baum U, Grabenbauer GG et al (2006) Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning. Radiother Oncol 81:190–195PubMedCrossRef Brunner TB, Baum U, Grabenbauer GG et al (2006) Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning. Radiother Oncol 81:190–195PubMedCrossRef
18.
go back to reference Van Laethem JL, Hammel P, Mornex F et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28:4450–4456CrossRef Van Laethem JL, Hammel P, Mornex F et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28:4450–4456CrossRef
19.
go back to reference Goodman KA, Regine WF, Dawson LA et al (2012) Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys 83:901–908PubMed Goodman KA, Regine WF, Dawson LA et al (2012) Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys 83:901–908PubMed
20.
go back to reference Spalding AC, Jee KW, Vineberg K et al (2007) Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 34:521–529PubMedCrossRef Spalding AC, Jee KW, Vineberg K et al (2007) Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 34:521–529PubMedCrossRef
21.
go back to reference Zhao L, Chen M, Ten Haken R et al (2007) Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol 82:153–159PubMedCrossRef Zhao L, Chen M, Ten Haken R et al (2007) Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol 82:153–159PubMedCrossRef
22.
go back to reference Sun W, Leong CN, Zhang Z, Lu JJ (2010) Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol 5:28PubMedCrossRef Sun W, Leong CN, Zhang Z, Lu JJ (2010) Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol 5:28PubMedCrossRef
23.
go back to reference Nagakawa T, Kobayashi H, Ueno K et al (1994) Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 73:1155–1162PubMedCrossRef Nagakawa T, Kobayashi H, Ueno K et al (1994) Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 73:1155–1162PubMedCrossRef
24.
go back to reference Crane CH, Wolff RA, Abbruzzese JL et al (2001) Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28:25–33PubMedCrossRef Crane CH, Wolff RA, Abbruzzese JL et al (2001) Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28:25–33PubMedCrossRef
25.
go back to reference Niedergethmann M, Rexin M, Hildenbrand R et al (2002) Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 26:1578–1587PubMedCrossRef Niedergethmann M, Rexin M, Hildenbrand R et al (2002) Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 26:1578–1587PubMedCrossRef
Metadata
Title
Comparison of four target volume definitions for pancreatic cancer
Guidelines for treatment of the lymphatics and the primary tumor
Authors
E. Fokas
C. Eccles
N. Patel
K.-Y. Chu
S. Warren
W. Gillies McKenna
T.B. Brunner
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Strahlentherapie und Onkologie / Issue 5/2013
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0332-3

Other articles of this Issue 5/2013

Strahlentherapie und Onkologie 5/2013 Go to the issue

Original article

What’s in a name?